DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
Recruiting · Phase 2 · NCT06176261
Conditions: Breast Cancer, Breast Cancer Female, Metastatic Triple-Negative Breast Carcinoma, ER Positive Breast Cancer, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, ER-negative Breast Cancer
At a glance
- Research payments reported, 2025
- $550,682
- U.S. investigators named
- 0
- Sites paid
- 1
- Planned or actual enrollment
- 58
About the trial
- Sponsor
- Nancy Lin, MD (with Daiichi Sankyo)
- Tested
- Datopotamab Deruxtecan (drug)
- Dates
- Started 2024-01-08; completion 2029-01-01
- Results posted
- Not yet
The purpose of this study is to test the safety and effectiveness of the study drug datopotamab deruxtecan in participants with metastatic breast cancer that has spread to the brain. The name of the study drug used in this research study is: Datopotamab deruxtecan (a type of antibody-drug conjugate)
From ClinicalTrials.gov, last updated 2026-08-06. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Daiichi Sankyo Inc. reported $550,682 in research payments for this study in 2025 (5 payments).
Products named: Datroway
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- Dana-Farber Cancer Institute $550,682
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.